Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nephropathy Formula No. 1 for T-Cell Immune Balance in CKD
NCT06796660Phase 1Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Dietary Supplement, Herbal Formulation
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Nephropathy Formula No. 1 in chronic kidney disease (CKD) (2 arms). Primary endpoint: Ratio of Th17 to Treg cells in T cell subsets at 12 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Nephropathy Formula No. 1
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06796660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06796660.